Compare LQDA & PAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | PAY |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.1B |
| IPO Year | 2020 | 2021 |
| Metric | LQDA | PAY |
|---|---|---|
| Price | $68.52 | $36.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $41.00 | $36.29 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | 48.57 |
| EPS | ★ 1.26 | 0.36 |
| Revenue | $158,320,000.00 | ★ $1,196,507,000.00 |
| Revenue This Year | $278.87 | $18.60 |
| Revenue Next Year | $57.13 | $18.89 |
| P/E Ratio | ★ $54.56 | $100.89 |
| Revenue Growth | ★ 1031.18 | 37.25 |
| 52 Week Low | $21.15 | $20.11 |
| 52 Week High | $93.61 | $45.31 |
| Indicator | LQDA | PAY |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 49.01 |
| Support Level | $30.48 | $27.82 |
| Resistance Level | $92.35 | $36.96 |
| Average True Range (ATR) | 3.20 | 1.71 |
| MACD | -0.54 | -0.85 |
| Stochastic Oscillator | 22.32 | 23.10 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.